IP Library Granted Patent US 6,995,019
Granted Patent B2
US 6,995,019 · App. 10/276,025 · Granted Feb 7, 2006

Fluorescent isothiocyanate (fitc) sinistrin, its production and use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,995,019
App. No.
10/276,025
Granted
Feb 7, 2006
Kind
B2
Abstract

The invention concerns fluorescein isothiocyanate-sinistrin (FITC-sinistrin), a method for its production, its use as a marker substance in a diagnostic agent and a corresponding diagnostic agent.

Claims (16)

1. A method for producing fluorescein isothiocyanate-sinistrin (FITC-sinistrin) comprising:

(a) reacting sinistrin with sodium hydride in a solvent to form a reaction mixture;

(b) adding FITC to the reaction mixture; and

(c) isolating FITC-sinistrin as a solid.

2. The method of claim 1 wherein the solvent is anhydrous dimethylformamide.

3. The method of claim 1 wherein the FITC-sinistrin is isolated by adding an aqueous ammonium chloride solution to the reaction mixture, extracting the FITC-sinistrin with diethyl ether and removing the diethyl ether to isolate solid FITC-sinistrin.

4. The method of claim 3 wherein the solid FITC is purified by at least one of recrystallization and gel filtration.

5. Fluorescein isothiocyanate-sinistrin (FITC-sinistrin) obtainable by the method of claim 1 .

6. A composition comprising fluorescein isothiocyanate-sinistrin (FITC-sinistrin) in a physiologically acceptable solution.

7. The composition of claim 6 wherein the solution comprises FITC-sinistrin in a concentration of 25–125 mg/ml.

8. A method for measuring renal function in a patient comprising:

administering to the patient a FITC-sinistrin;

beaming light onto the skin of the patient; and

detecting the fluorescent light emitted from the skin wherein the amount of fluorescence is related to the renal function of the patient.

9. The method of claim 8 wherein the FITC-sinistrin is prepared by the method of claim 9 .

10. The method of claim 8 wherein the FITC-sinistrin is administered in a dose of 5–50 mg/kg.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2015
From: ROCHE DIAGNOSTICS OPERATIONS, INC.
To: ROCHE DIABETES CARE, INC.
Reel/Frame 036008/0670 →